成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. 誘導(dǎo)疾病模型產(chǎn)品 Vitamin D Related/Nuclear Receptor
  2. 遺傳工程疾病模型 Estrogen Receptor/ERR
  3. 4-Hydroxytamoxifen

4-Hydroxytamoxifen  (Synonyms: 4-羥基他莫昔芬; (Z)-4-Hydroxytamoxifen; trans-4-Hydroxytamoxifen; (Z)-Afimoxifene)

目錄號(hào): HY-16950 純度: 99.95%
COA 產(chǎn)品使用指南 技術(shù)支持

4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) 是一種口服有效,選擇性的雌激素受體調(diào)節(jié)劑 (SERM)。4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) 基于 ER 介導(dǎo)的細(xì)胞核易位誘導(dǎo) CRISPR/Cas9 系統(tǒng)。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

4-Hydroxytamoxifen Chemical Structure

4-Hydroxytamoxifen Chemical Structure

CAS No. : 68047-06-3

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機(jī)構(gòu)(單位)一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥639
In-stock
5 mg ¥750
In-stock
10 mg ¥950
In-stock
25 mg ¥2050
In-stock
50 mg ¥4000
In-stock
100 mg   詢價(jià)  
200 mg   詢價(jià)  

* Please select Quantity before adding items.

Other Forms of 4-Hydroxytamoxifen:

查看 Estrogen Receptor/ERR 亞型特異性產(chǎn)品:

  • 生物活性

  • 實(shí)驗(yàn)參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) induces CRISPR/Cas9 systems based on ER mediated nucleus translocation[1][2][3][4].

IC50 & Target[1][2]

Estrogen receptor

3.3 nM (IC50)

CRISPR/Cas9

 

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
DU-145 EC50
10 μM
Compound: OH-TAM
Antiproliferative activity against human prostate, androgen receptor positive DU145 cells after 24 hrs by MTT assay
Antiproliferative activity against human prostate, androgen receptor positive DU145 cells after 24 hrs by MTT assay
[PMID: 25198997]
DU-145 IC50
15.3 μM
Compound: 4OHT
Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 33965842]
HEK293 IC50
0.07 μM
Compound: 4-OHT
Antagonist activity at luciferase-fused ERalpha in human HEK293 cells expressing eYFP assessed as reduction of E2-induced estrogenic activity after 2 hrs by BRET assay
Antagonist activity at luciferase-fused ERalpha in human HEK293 cells expressing eYFP assessed as reduction of E2-induced estrogenic activity after 2 hrs by BRET assay
[PMID: 26613635]
HEK293 IC50
0.79 nM
Compound: 4-OHT
Antagonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as reduction in E2-induced ER-alpha-mediated transcriptional activity by luciferase reporter gene assay
Antagonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as reduction in E2-induced ER-alpha-mediated transcriptional activity by luciferase reporter gene assay
[PMID: 30940565]
Ishikawa EC50
11.5 μM
Compound: OH-TAM
Antiproliferative activity against human ER-positive Ishikawa cells after 24 hrs by MTT assay
Antiproliferative activity against human ER-positive Ishikawa cells after 24 hrs by MTT assay
[PMID: 25198997]
Ishikawa IC50
3.57 μg/mL
Compound: 4-Hydroxy-Tamoxifen
Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay
[PMID: 28442256]
MCF-10A IC50
10 μM
Compound: OH-TAM
Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay
Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay
[PMID: 25198997]
MCF-10A IC50
21.5 μM
Compound: 4OHT
Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
[PMID: 35611405]
MCF7 IC50
0.0034 μM
Compound: 4-hydroxytamoxifen
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method
[PMID: 28105283]
MCF7 IC50
0.15 μM
Compound: 4-OHT
Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay
Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay
[PMID: 26613635]
MCF7 IC50
0.67 μM
Compound: 4OHT
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
[PMID: 35611405]
MCF7 IC50
0.95 μg/mL
Compound: 4-Hydroxy-Tamoxifen
Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay
[PMID: 28442256]
MCF7 IC50
10.1 μM
Compound: 4-OHT
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
[PMID: 30939353]
MCF7 IC50
15.6 μM
Compound: 4OHT
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 33965842]
MCF7 IC50
17.5 μM
Compound: 4-hydroxytamoxifen
Antiproliferative activity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay
[PMID: 31465222]
MCF7 IC50
20 μM
Compound: 4-hydroxytamoxifen
Cytotoxicity against tamoxifen-resistant human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method
Cytotoxicity against tamoxifen-resistant human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method
[PMID: 28105283]
MCF7 EC50
3.5 nM
Compound: 2a; 4OH-T
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
[PMID: 34251202]
MCF7 EC50
7.4 μM
Compound: OH-TAM
Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay
[PMID: 25198997]
MCF7 EC50
8.8 μM
Compound: OH-TAM
Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay
[PMID: 25198997]
MCF7 IC50
9.5 μM
Compound: 4OHT
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 30053783]
MCF7 IC50
9.9 nM
Compound: 2
Antiproliferative activity against human MCF7 cells after 6 days in presence of estradiol by CellTiter-Glo assay
Antiproliferative activity against human MCF7 cells after 6 days in presence of estradiol by CellTiter-Glo assay
[PMID: 29562737]
MDA-MB-231 IC50
18.43 μM
Compound: 4OHT
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay
[PMID: 35611405]
MDA-MB-231 IC50
6.51 μg/mL
Compound: 4-Hydroxy-Tamoxifen
Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay
[PMID: 28442256]
MDA-MB-231 EC50
7.8 μM
Compound: OH-TAM
Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay
[PMID: 25198997]
MDA-MB-231 EC50
8 μM
Compound: OH-TAM
Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay
[PMID: 25198997]
T47D IC50
0.01 μM
Compound: 4-OHT
Antagonist activity at ERalpha in human T47D-KBLuc cells assessed as inhibition of E2-induced transcriptional activity by luciferase reporter gene assay
Antagonist activity at ERalpha in human T47D-KBLuc cells assessed as inhibition of E2-induced transcriptional activity by luciferase reporter gene assay
[PMID: 26613635]
Vero IC50
15.1 μM
Compound: 4OHT
Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 33965842]
體外研究
(In Vitro)

4-Hydroxytamoxifen (Monohydroxytamoxifen) 是一種選擇性雌激素受體拮抗劑,[3H]oestradiol 與雌激素受體結(jié)合的 IC50 為 3.3 nM。4-Hydroxytamoxifen (10,100 nM) 能夠抑制[3H]oestradiol 與人 8 S 雌激素受體的結(jié)合[1]。
4-Hydroxytamoxifen 激活內(nèi)含肽連接的無(wú)活性 Cas9,減少脫靶 CRISPR 介導(dǎo)的基因編輯。在人類(lèi)細(xì)胞中,有條件激活的 Cas9 修飾靶基因組位點(diǎn)的特異性比野生型 Cas9 高 25 倍[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

4-Hydroxytamoxifen (0.2、1 和 5 μg/d,口服) 引起未成熟大鼠子宮濕重劑量相關(guān)降低[1]。
4-Hydroxytamoxifen (6 μg/0.1 mL 芝麻油,每天 1 次,皮下注射) 有效減弱完整和切除性腺的 C57BL/6 J 小鼠的兩性中甲基苯丙胺誘導(dǎo)的黑質(zhì)紋狀體多巴胺耗竭。4-Hydroxytamoxifen 不會(huì)改變紋狀體中的多巴胺含量水平[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

387.52

Formula

C26H29NO2

CAS 號(hào)
性狀

固體

顏色

White to off-white

中文名稱

4-羥基他莫昔芬

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn): 

DMSO 中的溶解度 : 50 mg/mL (129.03 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響,請(qǐng)使用新開(kāi)封的 DMSO)

Ethanol 中的溶解度 : 20 mg/mL (51.61 mM; 超聲助溶)

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 2.5805 mL 12.9026 mL 25.8051 mL
5 mM 0.5161 mL 2.5805 mL 5.1610 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效
儲(chǔ)備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用,-20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物實(shí)驗(yàn):

請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:
——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用;
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶

  • 方案 一

    請(qǐng)依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (5.37 mM); 澄清溶液

    此方案可獲得 ≥ 2.08 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL

    生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請(qǐng)依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (5.37 mM); 澄清溶液

    此方案可獲得 ≥ 2.08 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

    2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。

以下溶解方案,請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配,在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比; 如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶。

  • 方案 一

    請(qǐng)依序添加每種溶劑: 50% PEG300    50% Saline

    Solubility: 5 mg/mL (12.90 mM); 懸濁液; 超聲助溶

動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息:

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

由于實(shí)驗(yàn)過(guò)程有損耗,建議您多配一只動(dòng)物的量
請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網(wǎng)站選購(gòu)。 ,Tween 80,均可在 MCE 網(wǎng)站選購(gòu)。
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度,以下方案僅供參考,如有需要,請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
連續(xù)給藥周期超過(guò)半月以上,請(qǐng)謹(jǐn)慎選擇該方案。
請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.96%

參考文獻(xiàn)
Kinase Assay
[1]

Cytosol (200 μL) is incubated for 30 min at 4°C with different concentrations of oestradiol, tamoxifen and (4-Hydroxytamoxifen) or dihydroxytamoxifen administered in 10 μL methanol. Control tubes are incubated with 10 μL methanol alone and non-specific binding is determined in a parallel incubation of cytosol (200 μL) with methanol (10 μL) containing DES (5 × 106 M). [2,4,6,7-3H]Oestradiol solution (50 μL) in TED buffer is added to each tube to give a final concentration of 2 × 10-9 M. Incubation is continued for 4 h (4°C) and then 400 μL of a suspension of dextran-coated charcoal (250 mg % Norit A, 2.5 mg % dextran) in TED buffer are added and allowed to stand for 20 min. Tubes are centrifuged at 800 g for 10 min (4°C) and 400 μL samples of the supernatant are added to 10 mL tritium scintillator (6 g butyl PBD, 135 mL toluene, 720 ml dioxan, 100 g naphthalene, 45 mL absolute methanol). Samples are counted for 10 min in a liquid scintillation spectrometer. Counting efficiency is determined by external standardization (35-36 %). Results are represented as a percentage of the specifically bound radioactivity (c.p.m.) in the control tubes[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3]

Mice[3]
Animals of each sex are divided into two groups: one group receives 4-Hydroxytamoxifen [6 μg/0.1 mL sesame oil/day, subcutaneously (s.c.) starting at 06.00 h] injections for three consecutive days, while the other group receives an equivalent amount of sesame oil injection for 3 days. Four hours following the third injection, each group is then subdivided into two groups: one receives four cumulative doses of methamphetamine hydrochloride (10 mg/kg, s.c.), and the other receives a comparable volume of saline at 2-h intervals. Bilateral gonadectomy is performed under pentobarbital anesthesia (50 mg/kg, intraperitoneally). Five weeks after surgery,gonadectomized mice of each sex are randomly divided into six groups. Five groups of each sex receive three daily injections ofvarious concentrations of 4-Hydroxytamoxifen (0, 1.5, 3.0, 6.0, and 12.0 μg/0.1 mL sesame oil/day). Four hours following the third injection, mice receive four doses of methamphetamine (MA, 10 mg/kg) at 2-h intervals. The remaining group of each sex receives sesame oil pretreatment for three consecutive days, followed by saline injections, and serves as the control group[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效
儲(chǔ)備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用,-20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 2.5805 mL 12.9026 mL 25.8051 mL 64.5128 mL
5 mM 0.5161 mL 2.5805 mL 5.1610 mL 12.9026 mL
10 mM 0.2581 mL 1.2903 mL 2.5805 mL 6.4513 mL
15 mM 0.1720 mL 0.8602 mL 1.7203 mL 4.3009 mL
20 mM 0.1290 mL 0.6451 mL 1.2903 mL 3.2256 mL
25 mM 0.1032 mL 0.5161 mL 1.0322 mL 2.5805 mL
30 mM 0.0860 mL 0.4301 mL 0.8602 mL 2.1504 mL
40 mM 0.0645 mL 0.3226 mL 0.6451 mL 1.6128 mL
50 mM 0.0516 mL 0.2581 mL 0.5161 mL 1.2903 mL
DMSO 60 mM 0.0430 mL 0.2150 mL 0.4301 mL 1.0752 mL
80 mM 0.0323 mL 0.1613 mL 0.3226 mL 0.8064 mL
100 mM 0.0258 mL 0.1290 mL 0.2581 mL 0.6451 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱:

 

* 需求量:

* 客戶姓名:

 

* Email:

* 電話:

 

* 公司或機(jī)構(gòu)名稱:

   留言給我們:

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱:
4-Hydroxytamoxifen
目錄號(hào):
HY-16950
需求量: